Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SM17 Monoclonal Antibody Injection (Subcutaneous) in Chinese Healthy Participants

NCT07466940 is registered in ClinicalTrials.gov with SinoMab BioScience Ltd as lead sponsor.

NCT NCT07466940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07466940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SM17 Monoclonal Antibody Injection (Subcutaneous) in Chinese Healthy Participants
Lead sponsor
SinoMab BioScience Ltd
Phase
Phase 1
Overall status
Completed
Start date
October 14, 2025
Completion date
February 3, 2026
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, atopic dermatitis, inflammatory bowel disease